1. Home
  2. Clinical Topics
  3. FDA approves new radiopharmaceutical for certain GI cancers
Clinical TopicsDrugs and DevicesOncologyWeb Exclusives
fda radiopharmaceutical gi cancer

FDA approves new radiopharmaceutical for certain GI cancers

Share

On Jan. 26, the U.S. Food and Drug Administration (FDA) approved the first radiopharmaceutical, Lutathera (lutetium Lu 177 dotatate), for the treatment of gastroenteropancreatic neuroendocrine tumors.

Read more via Fda.gov.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts